Trial Profile
Evaluation of the Effectiveness of Eliquis (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 06 Mar 2017 Status changed from active, no longer recruiting to completed.
- 28 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 16 Oct 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.